NASDAQ: MBOTMicrobot Medical Inc Stock
$0.87-0.02 (-2.25%)
Updated Apr 19, 2024
MBOT Price
$0.87
Fair Value Price
$0.22
Market Cap
$12.46M
52 Week Low
$0.86
52 Week High
$4.37
P/E
-0.82x
P/B
2.77x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.74M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.85
Operating Cash Flow
-$9M
Beta
0.99
Next Earnings
May 15, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MBOT Overview
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MBOT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MBOT ($0.87) is overvalued by 285.96% relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MBOT ($0.87) is not significantly undervalued (285.96%) relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MBOT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MBOT due diligence checks available for Premium users.
Be the first to know about important MBOT news, forecast changes, insider trades & much more!
MBOT News
Valuation
MBOT fair value
Fair Value of MBOT stock based on Discounted Cash Flow (DCF)
Price
$0.87
Fair Value
$0.22
Overvalued by
288.19%
MBOT ($0.87) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MBOT ($0.87) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MBOT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MBOT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.82x
Industry
47.12x
Market
40.51x
MBOT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.77x
Industry
3.46x
MBOT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MBOT's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
MBOT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.3M
Liabilities
$3.8M
Debt to equity
0.85
MBOT's short-term assets ($7.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MBOT's short-term assets ($7.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MBOT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MBOT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$3.0M
Financing
$0.0
MBOT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MBOT vs Medical Stocks
Microbot Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.